Sign in

CIK 0001818794

  • Large accelerated filer

Dyne Therapeutics, Inc.

Sign in to watch
Ticker
DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
364883909
Phone
+1 781-786-8230
Business address
1560 TRAPELO ROAD, WALTHAM, MA, 02451
Open-market buys, last 90 days
$40,000
in 1 filing
Open-market sales, last 90 days
$421,679
in 7 filings, $422K under 10b5-1 plans

Net −$381,679. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2021-09-20 Scalzo Richard William Sale −367 $15.61 $6K 11,098
2021-09-20 McNeill Jonathan Sale −545 $15.61 $9K 36,365
2021-09-20 Brumm Joshua T Sale −3,425 $15.61 $53K 103,602
2021-09-20 Beskrovnaya Oxana Chief Scientific Officer Sale −617 $15.61 $10K 18,672
2021-07-13 Atlas Venture Fund XI, L.P. 10% owner Other disposition −814,013 7,326,117
2021-07-10 McNeill Jonathan Grant or award · Stock Option (right to buy) +25,000 25,000
2021-06-02 Beskrovnaya Oxana Chief Scientific Officer Grant or award · Stock Option (right to buy) +110,000 110,000
2021-05-26 Stehman-Breen Catherine Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-05-26 Kersten Dirk Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-05-26 Klein Lawrence Otto Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-05-26 HURWITZ EDWARD Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-05-26 Rhodes Jason P Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-05-26 Lubner David Charles Director Grant or award · Stock Option (right to buy) +19,596 19,596
2021-03-02 Farwell Wildon Chief Medical Officer Grant or award +50,000 50,000
2021-03-02 Farwell Wildon Chief Medical Officer Grant or award · Stock Option (right to buy) +250,000 250,000
2020-09-21 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion +2,145,045 2,145,045
2020-09-21 RA CAPITAL MANAGEMENT, L.P. 10% owner Purchase +660,000 $19.00 $12.5M 2,805,045
2020-09-21 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion · Series B Preferred Stock −7,114,905 0
2020-09-21 MPM BIOVENTURES 2018, L.P. 10% owner Conversion +4,614,943 4,614,943
2020-09-21 MPM BIOVENTURES 2018, L.P. 10% owner Conversion +245,279 245,279

Page 37 of 41 · 818 trades